|
Dyax is arming the war against disease. The biopharmaceutical company develops drugs from its proprietary bacteriophage (phage) display binding technology that rapidly identifies proteins, peptides, and antibodies it can use to treat disease. Using phages to identify useful genetic codes, it primarily focuses on oncology and inflammation remedies. Dyax's lead drug candidate, DX-88, may be used to treat hereditary angioedema and to reduce blood loss during cardiopulmonary bypass surgeries -- it is currently undergoing clinical trials. The company has numerous other products in its discovery and development pipeline, including key candidate DX-2240, which is designed to inhibit cancerous tumor growth.
|
| | | Contact Information | |
Address: |
300 Technology Sq.
Cambridge, MA 02139
| | Phone: | 617-225-2500 | | Fax: | 617-225-2501 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 43.40 M | | Revenue Growth (1 yr): | 66.40% | | Employees (2008): | 164 | | Employee Growth (1 yr): | (-7.30%) |
|
|
Key People
| | • |
Chairman:
Henry E. Blair
| | • |
President, CEO, and Director:
Gustav A. Christensen
| | • |
EVP and CFO:
George Migausky
|
|
|
